CBRS20023, Dhakal, EA1181, Breast Cancer, Paclitaxel Docetaxel Trastuzumab Pertuzumab
How well do paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy
after surgery in patients with HER2-positive stage II-IIIa breast cancer?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating
further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast
cancer who have no cancer remaining at surgery (either in the breast or underarm lymph
nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy,
such as paclitaxel, work in different ways to stop the growth of tumor cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work
by attaching themselves to specific molecules (receptors) on the surface of tumor
cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals
that tell the cells to grow are blocked and the tumor cell may be marked for destruction
by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable
fewer chemotherapy drugs to be given without compromising patient outcomes compared
to the usual treatment.
Study Reference #: CBRS20023
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Tina Bowdish
Phone: +1 585-275-9475
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search